Design, synthesis and biological evaluation of novel pyrenyl derivatives as anticancer agents.
Debasish Bandyopadhyay, Jorge L Sanchez, Adrian M Guerrero, Fang-Mei Chang, Jose C Granados, John D Short, Bimal K Banik
文献索引:Eur. J. Med. Chem. 89 , 851-62, (2014)
全文:HTML全文
摘要
Polycyclic aromatic hydrocarbons are widespread in nature with a toxicity range from non-toxic to extremely toxic. A series of pyrenyl derivatives has been synthesized following a four-step strategy where the pyrene nucleus is attached with a basic heterocyclic moiety through a carbon linker. Virtual screening of the physicochemical properties and druggability has been carried out. The cytotoxicity of the compounds (1-8) have been evaluated in vitro against a small panel of human cancer cell lines which includes two liver cancer (HepG2 and Hepa 1-6), two colon cancer (HT-29 and Caco-2) and one each for cervical (HeLa) and breast (MCF-7) cancer cell lines. The IC50 data indicate that compound 6 and 8 are the most effective cytotoxic agents in the present set of pyrenyl derivatives, suggesting that having a 4-carbon linker is more effective than a 5-carbon linker and the presence of amide carbonyl groups in the linker severely reduces the efficacy of the compound. The compounds showed selectivity toward cancer cells at lower doses (<5 μM) when compared with the normal hepatocytes. The mechanism of action supports the cell death through apoptosis in a caspase-independent manner without cleavage of poly (ADP-ribose) polymerase (PARP), even though the compounds cause plasma membrane morphological changes. The compounds, whether highly cytotoxic or mildly cytotoxic, localize to the membrane of cells. The compounds with either a piperidine ring (6) or an N-methyl piperazine (8) in the side chain were both capable of circumventing the drug resistance in SKOV3-MDR1-M6/6 ovarian cancer cells overexpressing P-glycoprotein. Qualitative structure-activity relationship has also been studied.Copyright © 2014. Published by Elsevier Masson SAS.
相关化合物
相关文献:
2015-06-01
[Bioresour. Technol. 185 , 185-93, (2015)]
2015-02-01
[Macromol. Biosci. 15(2) , 200-14, (2015)]
2015-02-01
[Drug Test. Anal. 7(2) , 131-42, (2015)]
2014-12-30
[Int. J. Pharm. 477(1-2) , 495-505, (2014)]
2014-11-01
[J. Immunol. Methods 413 , 12-24, (2014)]